The kidney and the skeleton seem like unrelated organs — one filters blood and regulates fluid balance, the other provides structural support and mineral storage. In reality, they are locked in one of biology’s most intricate regulatory partnerships. The kidney activates vitamin D, regulates phosphate excretion, responds to parathyroid hormone, and produces factors that directly govern bone remodeling. When kidney function declines, this partnership breaks down catastrophically. This can also happen due to substance abuse and improper THC detox.
In 2006, the unifying term “CKD-associated mineral and bone disorder” (CKD-MBD) was proposed for all bone and mineral abnormalities combined in chronic kidney disease — and has been widely accepted by the nephrology community since.
CKD-MBD is not merely a bone disease. It involves a number of interconnected issues in mineral metabolism, bone health, and cardiovascular calcification, which are linked to a lower quality of life and shorter life expectancy. Understanding this syndrome — its mechanisms, its manifestations, and its management — is essential for every patient with CKD and every clinician who cares for them.
Defining CKD-MBD: The 2006 Landmark
What the KDIGO Definition Established
According to the Kidney Disease: Improving Global Outcomes (KDIGO) 2006 guidelines, CKD-MBD is defined as “a systemic disorder of mineral and bone metabolism due to CKD manifested by either one or a combination of the following: abnormalities of calcium, phosphorus, PTH, or vitamin D metabolism; abnormalities in bone turnover, mineralization, volume, linear growth, or strength; or vascular or other soft tissue calcification.”
This three-part definition was revolutionary because it formally acknowledged what clinicians had long observed but never systematically classified: that kidney disease produces a syndrome extending far beyond the kidney itself, simultaneously damaging bone and blood vessels through shared pathophysiological mechanisms.
Why the Old Term “Renal Osteodystrophy” Was Insufficient
Before 2006, “renal osteodystrophy” was used to describe bone disease in CKD. The term CKD-MBD describes a broader clinical syndrome — a systemic disorder of mineral and bone metabolism due to CKD manifested by abnormalities in bone and mineral metabolism and/or extra-skeletal calcification.
Renal osteodystrophy remains a valid term — but now reserved specifically for the morphological bone abnormalities, assessed by bone biopsy, that are one component of the broader CKD-MBD syndrome.
The Pathophysiology: A Cascade of Mineral Dysregulation
The Sequence Begins Early
CKD-MBD does not wait for dialysis to begin. Derangements induced by CKD are multiple, ranging from the classically described disturbances of vitamin D metabolism, calcium, and phosphate balance, through increased levels of parathyroid hormone (secondary hyperparathyroidism) to the more recently recognized increases in fibroblast growth factor 23 (FGF23) and sclerostin, or decreased serum klotho levels.
The cascade initiates as early as CKD Stage 3 (eGFR < 60 mL/min) — long before patients feel unwell or require dialysis.
The Key Players: A Systems Biology View
Phosphate: As nephron mass decreases, phosphate excretion per remaining nephron must increase. The kidney signals bone and intestine to manage phosphate load through:
- FGF-23: a hormone produced by osteocytes (bone cells) that increases phosphate excretion and suppresses vitamin D activation
- As CKD advances, FGF-23 rises dramatically — one of the earliest detectable CKD-MBD biomarkers
- Eventually, even massively elevated FGF-23 cannot compensate → hyperphosphatemia develops
Vitamin D: The kidney converts 25-hydroxyvitamin D to its active form, calcitriol (1,25-dihydroxyvitamin D). As kidney function declines:
- Calcitriol production falls
- Intestinal calcium absorption decreases
- Serum calcium falls → triggers parathyroid gland stimulation
Parathyroid Hormone (PTH): Hypocalcemia and hyperphosphatemia both stimulate parathyroid hormone secretion:
- PTH mobilizes calcium from bone (osteoclast activation)
- PTH increases renal phosphate excretion (compensatory while kidney function allows)
- Chronic PTH excess → secondary hyperparathyroidism → progressive bone destruction
Klotho: FGF-23 inhibits phosphate reabsorption and calcitriol synthesis in the kidney; klotho acts as its co-receptor and also has independent protective functions. Klotho levels fall dramatically in CKD — contributing to vascular calcification, accelerated aging phenotype, and cardiovascular risk independent of mineral abnormalities.
The Pathophysiological Cascade Summary
| Stage | Key Event | Clinical Consequence |
| Early CKD (Stage 3) | FGF-23 rises; calcitriol falls | Subclinical secondary HPT begins |
| Moderate CKD (Stage 3b–4) | PTH rises; phosphate retention | Bone remodeling abnormalities begin |
| Advanced CKD (Stage 4–5) | Hyperphosphatemia develops | Vascular calcification; severe HPT |
| Dialysis (Stage 5D) | All derangements severe; exogenous management required | High fracture risk; high cardiovascular mortality |
Bone Disease in CKD: The Forms of Renal Osteodystrophy
Classification by Bone Biopsy
Essentially, bone biopsies should evaluate bone turnover, mineralization and volume (following the useful acronym TMV). Different patterns of renal osteodystrophy are usually described: high-turnover osteitis fibrosa or mild hyperparathyroidism, low-turnover adynamic bone disease and osteomalacia, and the mixed form named uremic osteodystrophy.
Osteitis Fibrosa (High Turnover):
- Caused by excess PTH driving excessive osteoclast and osteoblast activity
- Bone is rapidly resorbed and replaced with disorganized, structurally inferior tissue
- Subperiosteal resorption visible on X-ray (classic radiological sign)
- Most common in severe, uncontrolled secondary hyperparathyroidism
Adynamic Bone Disease (Low Turnover):
- Paradoxically, the opposite problem — bone turnover is suppressed below normal
- Associated with over-suppression of PTH (often from overzealous treatment) or diabetes
- Bone cannot repair microfractures → accumulating skeletal fragility despite “normal” biochemistry
- Increasingly prevalent in dialysis patients, particularly those with diabetes
Osteomalacia (Mineralization Defect):
- Inadequate mineralization of newly formed bone matrix
- Primarily caused by vitamin D deficiency or aluminum toxicity (historical, now rare with elimination of aluminum-containing antacids and dialysate)
- “Soft” bones: pain, proximal muscle weakness, pathological fractures
Uremic/Mixed Osteodystrophy:
- Features of both high and low turnover
- Most complex to manage — treatment targeting one component may worsen the other
Clinical Consequences of Bone Disease
- Fracture risk: CKD patients have substantially higher fracture rates than the general population; hip fractures carry very high mortality in dialysis patients
- Bone pain: particularly from osteitis fibrosa — aching, diffuse skeletal pain that is frequently undertreated
- Skeletal deformity: particularly in children, where growth plate involvement causes linear growth failure and bone deformity
- Muscle weakness: proximal myopathy from vitamin D deficiency and uremic milieu
Vascular Calcification: The Silent Killer
Why Vascular Calcification Is Uniquely Dangerous in CKD
Vascular calcification — the pathological deposition of calcium phosphate mineral in arterial walls — occurs in three forms in CKD:
- Intimal calcification: atherosclerotic plaques that calcify, causing coronary and peripheral artery disease
- Medial calcification (Mönckeberg’s sclerosis): calcium deposits in the smooth muscle layer of arterial walls — independent of atherosclerosis, causing arterial stiffness and reduced compliance
- Valvular calcification: particularly affecting the aortic and mitral valves, causing hemodynamic compromise
Extra-skeletal complications of altered bone metabolism contribute to the dismal risk to which CKD patients are exposed. Cardiovascular and soft tissue calcifications and left ventricular hypertrophy are among the most serious.
The Mechanism: Competing Inhibitors
Vascular calcification in CKD results from two simultaneous processes:
Promoters of calcification (elevated in CKD):
- High serum phosphate — calcium phosphate precipitation in vessel walls
- High calcium × phosphate product
- Apoptotic vascular smooth muscle cells releasing calcification-nucleating matrix vesicles
Inhibitors of calcification (depleted in CKD):
- Fetuin-A: serum protein that prevents calcium phosphate crystal formation — levels fall in CKD
- Pyrophosphate: endogenous calcification inhibitor — produced partly by alkaline phosphatase substrates
- Klotho: suppresses vascular smooth muscle calcification
- Matrix Gla protein: vitamin K-dependent calcification inhibitor — often depleted in CKD due to dietary restriction and medication effects
When inhibitors are depleted and promoters accumulate, the balance shifts irreversibly toward calcification.
Diagnosis and Monitoring
Laboratory Targets (KDIGO 2017 Update)
| Parameter | Recommended Monitoring Frequency | Target Range |
| Serum phosphate | Monthly (dialysis); 3–6 monthly (CKD 3b–5) | Maintain within normal laboratory range |
| Serum calcium | Monthly (dialysis); 3–6 monthly (CKD 3b–5) | Normal range; avoid hypercalcemia |
| PTH (intact) | Every 3 months (dialysis); 6–12 monthly (CKD 3b–5) | 2–9× upper limit of normal (dialysis) |
| 25-OH Vitamin D | Annually | Correct deficiency/insufficiency |
| Alkaline phosphatase | Every 12 months (or with PTH if elevated) | Within normal range |
Imaging for Vascular Calcification
- Lateral abdominal X-ray: simple, inexpensive assessment of aortic calcification
- Echocardiography: valvular calcification; left ventricular hypertrophy
- Coronary artery calcium scoring (CT): research and selected clinical use
Treatment: A Multifaceted Approach
Phosphate Management
Phosphate control is the cornerstone of CKD-MBD management:
Dietary restriction: limit foods high in inorganic phosphate (food additives, processed foods — absorbed more readily than organic phosphate); protein restriction must be balanced against malnutrition risk
Phosphate binders (taken with meals to bind dietary phosphate in the gut):
| Binder Class | Examples | Key Considerations |
| Calcium-based | Calcium carbonate, calcium acetate | Effective; risk of hypercalcemia and vascular calcification with high doses |
| Non-calcium, aluminum-free | Sevelamer (carbonate/hydrochloride) | Neutral calcium effect; may reduce vascular calcification |
| Lanthanum carbonate | Fosrenol | Effective; long-term lanthanum accumulation concerns |
| Iron-based | Ferric citrate, sucroferric oxyhydroxide | Simultaneous iron supplementation benefit |
Adequate dialysis: both hemodialysis and peritoneal dialysis remove phosphate — dialysis adequacy directly affects phosphate control
Vitamin D and PTH Management
- Native vitamin D (cholecalciferol/ergocalciferol): correct 25-OH vitamin D deficiency — benefits parathyroid suppression, muscle function, and immune regulation
- Active vitamin D analogues (calcitriol, paricalcitol, alfacalcidol): suppress PTH secretion; risk of hypercalcemia and hyperphosphatemia
- Calcimimetics (cinacalcet, etelcalcetide): increase calcium-sensing receptor sensitivity in parathyroid glands → suppress PTH without raising calcium or phosphate; preferred when hypercalcemia limits vitamin D use
- Parathyroidectomy: for severe, medically refractory secondary hyperparathyroidism — increasingly less common with calcimimetic availability
Conclusion
CKD-Mineral and Bone Disorder represents one of the most consequential and complex systemic complications of chronic kidney disease. CKD leads to numerous disturbances of mineral and bone metabolism which are an important cause of morbidity and mortality and of decreased quality of life — comprising abnormalities in circulating biomarkers, abnormal bone morphology, and extraskeletal calcifications.
The ISN Nexus Symposium on “Bone and the Kidney” — communicated to Japanese nephrologists through the 2006 JSN newsletter — exemplified the international scientific community’s recognition that CKD-MBD demanded a unified conceptual framework, interdisciplinary collaboration, and dedicated research investment. That investment has paid off: the KDIGO guidelines, calcimimetic therapies, non-calcium phosphate binders, and the expanding understanding of FGF-23 and klotho have all transformed management since 2006.
Your next steps if you have CKD and are concerned about bone and mineral health:
- Ask your nephrologist what your current PTH, phosphate, calcium, and vitamin D levels are — and what the targets are for your specific CKD stage
- Understand that phosphate binders must be taken with meals — not between meals — to work effectively; this timing detail is frequently misunderstood
- Request a dietary consultation with a renal dietitian — phosphate restriction is highly diet-specific and requires individualized guidance beyond a generic “avoid dairy” instruction
- Ask about vascular calcification assessment — a lateral abdominal X-ray or echocardiogram can detect calcification that may change your treatment targets
- If you experience new bone pain, muscle weakness, or unexplained fractures, report these promptly — they may indicate undertreated CKD-MBD requiring treatment intensification or bone biopsy
- Understand that CKD-MBD management is lifelong and requires regular monitoring — laboratory targets that are appropriate at CKD Stage 3 may need adjustment as your kidney function evolves